基于分子分型的子宫内膜癌免疫治疗

doi:10.3760/cma.j.cn371439-20220408-00138

摘要/Abstract

摘要：

子宫内膜癌由癌症基因组图谱计划通过基因组序列分析确定了4种分子亚型。基于各亚型不同免疫特点，选择适合的免疫治疗药物的临床试验在多个国家展开并取得重要进展。临床主要应用的免疫检查点抑制剂有抗程序性细胞死亡蛋白-1/程序性死亡配体-1抗体和聚腺苷二磷酸核糖聚合酶抑制剂。依据不同免疫检查点抑制剂针对的靶点特性优化药物选择和药物配伍可能为子宫内膜癌的免疫治疗提供新机遇，为提高生存率带来新的曙光。

关键词: 子宫内膜肿瘤, 分子分型, 免疫治疗, 免疫检查点抑制剂, 生存率

Abstract:

Endometrial cancer has been identified by The Cancer Genome Atlas program with four molecular subtypes by genome sequence analysis. Clinical trials to select suitable immunotherapeutic agents based on the different immune characteristics of each subtype have been conducted in several countries and have made important progress. The main clinical applications of immune checkpoint inhibitors include anti-programmed cell death protein-1/programmed death-ligand 1 antibodies and poly ADP-ribose polymerase inhibitors. Optimizing drug selection and drug combination based on the target characteristics of different immune checkpoint inhibitors may provide new opportunities for immunotherapy of endometrial cancer and bring new light to improve survival rates.

Key words: Endometrial neoplasms, Molecular typing, Immunotherapy, Immune checkpoint inhibitors, Survival rate

徐秋月, 马咸梅, 岳琦. 基于分子分型的子宫内膜癌免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(11): 700-704.

Xu Qiuyue, Ma Xianmei, Yue Qi. Immunotherapy for endometrial carcinoma based on molecular typing[J]. Journal of International Oncology, 2022, 49(11): 700-704.

参考文献 32

[1]	中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 501-512. DOI: 10.19401/j.cnki.1007-3639.2021.06.08. doi: 10.19401/j.cnki.1007-3639.2021.06.08
[2]	Baiden-Amissah REM, Annibali D, Tuyaerts S, et al. Endometrial cancer molecular characterization: the key to identifying high-risk patients and defining guidelines for clinical decision-making?[J]. Cancers (Basel), 2021, 13(16): 3988. DOI: 10.3390/cancers13163988. doi: 10.3390/cancers13163988
[3]	Beinse G, Rance B, Just PA, et al. Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments[J]. Int J Gynecol Cancer, 2020, 30(5): 640-647. DOI: 10.1136/ijgc-2019-000871. doi: 10.1136/ijgc-2019-000871
[4]	Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma[J]. Gynecol Oncol, 2017, 145(1): 200-207. DOI: 10.1016/j.ygyno.2016.12.015. doi: S0090-8258(16)31680-8 pmid: 28040204
[5]	McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses[J]. J Pathol, 2018, 244(5): 538-549. DOI: 10.1002/path.5034. doi: 10.1002/path.5034
[6]	Imboden S, Nastic D, Ghaderi M, et al. Phenotype of POLE-mutated endometrial cancer[J]. PLoS One, 2019, 14(3): e0214318. DOI: 10.1371/journal.pone.0214318. doi: 10.1371/journal.pone.0214318
[7]	Akhtar M, Al Hyassat S, Elaiwy O, et al. Classification of endometrial carcinoma: new perspectives beyond morphology[J]. Adv Anat Pathol, 2019, 26(6): 421-427. DOI: 10.1097/PAP.0000000000000251. doi: 10.1097/PAP.0000000000000251 pmid: 31567131
[8]	Yamashita H, Nakayama K, Ishikawa M, et al. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer[J]. Oncotarget, 2017, 9(5): 5652-5664. DOI: 10.18632/oncotarget.23790. doi: 10.18632/oncotarget.23790
[9]	Goebel EA, Vidal A, Matias-Guiu X, et al. The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future[J]. Virchows Arch, 2018, 472(6): 885-896. DOI: 10.1007/s00428-017-2279-8. doi: 10.1007/s00428-017-2279-8
[10]	Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447): 67-73. DOI: 10.1038/nature12113. doi: 10.1038/nature12113
[11]	Uppendahl L, Mullany SA, Winterhoff B. Molecular characterization of endometrial cancer and therapeutic implications[J]. Curr Opin Obstet Gynecol, 2017, 29(1): 35-39. DOI: 10.1097/GCO.0000000000000342. doi: 10.1097/GCO.0000000000000342
[12]	Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the the International Society Of Gynecological Pathologists[J]. Int J Gynecol Pathol, 2019, 38 Suppl 1 (Iss 1 Suppl 1): S64-S74. DOI: 10.1097/PGP.0000000000000518. doi: 10.1097/PGP.0000000000000518
[13]	Gargiulo P, Della Pepa C, Berardi S, et al. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated endometrial cancers: new candidates for checkpoint blockade immunotherapy?[J]. Cancer Treat Rev, 2016, 48: 61-68. DOI: 10.1016/j.ctrv.2016.06.008. doi: 10.1016/j.ctrv.2016.06.008 pmid: 27362548
[14]	Piulats JM, Matias-Guiu X. Immunotherapy in endometrial cancer: in the nick of time[J]. Clin Cancer Res, 2016, 22(23): 5623-5625. DOI: 10.1158/1078-0432.CCR-16-1820. doi: 10.1158/1078-0432.CCR-16-1820 pmid: 27697995
[15]	Paleari L, Pesce S, Rutigliani M, et al. New insights into endometrial cancer[J]. Cancers (Basel), 2021, 13(7): 1496. DOI: 10.3390/cancers13071496. doi: 10.3390/cancers13071496
[16]	Eggink FA, Van Gool IC, Leary A, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition[J]. Oncoimmunology, 2017, 6(2): e1264565. DOI: 10.1080/2162402X.2016.1264565. doi: 10.1080/2162402X.2016.1264565
[17]	Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, et al. Immune checkpoint inhibitors in endometrial cancer[J]. Crit Rev Oncol Hematol, 2021, 161: 103306. DOI: 10.1016/j.critrevonc.2021.103306. doi: 10.1016/j.critrevonc.2021.103306
[18]	Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer[J]. Crit Rev Oncol Hematol, 2020, 152: 102973. DOI: 10.1016/j.critrevonc.2020.102973. doi: 10.1016/j.critrevonc.2020.102973
[19]	Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704. DOI: 10.1146/annurev.immunol.26.021607.090331. doi: 10.1146/annurev.immunol.26.021607.090331 pmid: 18173375
[20]	Tsimberidou AM, Vo HH, Subbiah V, et al. Pembrolizumab in patients with advanced metastatic germ cell tumors[J]. Oncologist, 2021, 26(7): 558-e1098. DOI: 10.1002/onco.13682. doi: 10.1002/onco.13682
[21]	Markham A. Dostarlimab: first approval[J]. Drugs, 2021, 81(10): 1213-1219. DOI: 10.1007/s40265-021-01539-5. doi: 10.1007/s40265-021-01539-5 pmid: 34106455
[22]	Konstantinopoulos PA, Liu JF, Luo W, et al. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC)[J]. J Clin Oncol, 2019, 37(15_suppl): 5502. DOI: 10.1200/JCO.2019.37.15_suppl.5502. doi: 10.1200/JCO.2019.37.15_suppl.5502
[23]	Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer[J]. Am Soc Clin Oncol Educ Book, 2020, 40: 1-7. DOI: 10.1200/EDBK_280503. doi: 10.1200/EDBK_280503 pmid: 32213091
[24]	Antill YC, Kok PS, Robledo K, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase Ⅱ PHAEDRA trial (ANZGOG1601)[J]. J Clin Oncol, 2019, 37(15_suppl): 5501. DOI: 10.1200/JCO.2019.37.15_SUPPL.5501. doi: 10.1200/JCO.2019.37.15_SUPPL.5501
[25]	Monestier S, Dalle S, Mortier L, et al. Effectiveness and safety of nivolumab in patients with advanced melanoma: a multicenter, observational study[J]. Int J Cancer, 2021, 148(11): 2789-2798. DOI: 10.1002/ijc.33467. doi: 10.1002/ijc.33467 pmid: 33428772
[26]	Santin AD, Bellone S, Buza N, et al. Regression of chemotherapy-resistant polymerase ε (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab[J]. Clin Cancer Res, 2016, 22(23): 5682-5687. DOI: 10.1158/1078-0432.CCR-16-1031. doi: 10.1158/1078-0432.CCR-16-1031 pmid: 27486176
[27]	Lim JSJ, Tan DSP. Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors[J]. Cancers (Basel), 2017, 9(8): 109. DOI: 10.3390/cancers9080109. doi: 10.3390/cancers9080109
[28]	Slade D. PARP and PARG inhibitors in cancer treatment[J]. Genes Dev, 2020, 34(5/6): 360-394. DOI: 10.1101/gad.334516.119. doi: 10.1101/gad.334516.119
[29]	Li H, Liu ZY, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications[J]. Mol Cancer, 2020, 19(1): 107. DOI: 10.1186/s12943-020-01227-0. doi: 10.1186/s12943-020-01227-0 pmid: 32563252
[30]	Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study[J]. J Clin Oncol, 2017, 35(36): 4050-4056. DOI: 10.1200/JCO.2017.73.3675. doi: 10.1200/JCO.2017.73.3675 pmid: 28837405
[31]	Antill Y, Kok PS, Robledo K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial[J]. J Immunother Cancer, 2021, 9(6): e002255. DOI: 10.1136/jitc-2020-002255. doi: 10.1136/jitc-2020-002255
[32]	Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer[J]. J Clin Oncol, 2020, 38(26): 2981-2992. DOI: 10.1200/JCO.19.02627. doi: 10.1200/JCO.19.02627 pmid: 32167863